Molecular modeling methodologies (molecular dynamics, conformational searching, Monte Carlo) used data from the crystallized structure of bovine rhodopsin (excluding the intracellular and extracellular domains), which is the only 7-transmembrane receptor crystallized to date, in order to develop a model of the delta-opioid receptor by in silico methods; i.e., computer-directed mutagenesis to ensure that the sequence of the rhodopsin format coincided with that of the delta-opioid receptor by exchanging specific amino acids. A variety of delta agonists and antagonists based on the Dmt-Tic pharmacophore derived from X-ray diffraction analyses of three selective compounds with different specificities (delta- and mu-opioid receptor selective, and non-selective), as well as specific mu-opioid receptor agonists, which should have very low affinity with the delta-opioid receptor, were docked into the proposed binding pocket. The ligand-binding domain was initially determined from data on site-directed mutagenesis obtained from the literature. The minimized molecular models of the ligands reflected their known biological activities and receptor affinities and conformational changes in the peptides were initially examined by 1-H NMR (COSY, NOESY, HOHAHA, ROESY, DQF-COSY experiments), CD under varying solvent and temperature conditions. In terms of the ligands, the aromatic ring distance may be a singularly important characteristic which distinguishes delta-opioid receptor antagonists and agonists for both mu- and delta-opioid receptors providing a presumptive """"""""receptor-bound conformation"""""""" in spite of the inherent flexibility of the peptide. As anticipated, mu-opioid receptor agonists exhibited a poor fit in the delta receptor pocket region, confirming the application of this methodology. The topographical features observed with the Dmt-Tic pharmacophore differentiate it from all other peptides and its interaction with select side-chains in the receptor pocket. The data suggest that the presumed receptor-bound conformation of the peptide ligand and receptor involves stacking between aromatic rings and hydrogen bonding and that mu-opioid agonists poorly interacted with those residues specific for delta ligands. Furthermore, there appeared to be two regions in which agonists and antagonists interact, one of which is shared by these compounds. Thus, intra-ring distance of delta-opioid receptor antagonists may portend biological differences due to its fit within its receptor. Peptide analogues with dual receptor binding characteristics or selectivity for the mu-opioid receptor equally assisted in the application of molecular modeling in a predictive mode. Thus, model of the delta receptor and our delta- and mu-opioid antagonist and agonist pharmacophores will serve as scaffolds in the design of new potent ligands.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Intramural Research (Z01)
Project #
1Z01ES090078-10
Application #
7007485
Study Section
(LCBR)
Project Start
Project End
Budget Start
Budget End
Support Year
10
Fiscal Year
2004
Total Cost
Indirect Cost
Name
U.S. National Inst of Environ Hlth Scis
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Balboni, Gianfranco; Onnis, Valentina; Congiu, Cenzo et al. (2007) Further studies on the effect of lysine at the C-terminus of the Dmt-Tic opioid pharmacophore. Bioorg Med Chem 15:3143-51
Li, Tingyou; Jinsmaa, Yunden; Nedachi, Masahiro et al. (2007) Transformation of mu-opioid receptor agonists into biologically potent mu-opioid receptor antagonists. Bioorg Med Chem 15:1237-51
Li, Tingyou; Shiotani, Kimitaka; Miyazaki, Anna et al. (2007) Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed mu-agonist/delta-antagonist and dual mu-agonist/delta-agonist opioid ligands. J Med Chem 50:2753-66
Marczak, Ewa D; Jinsmaa, Yunden; Li, Tingyou et al. (2007) [N-allyl-Dmt1]-endomorphins are micro-opioid receptor antagonists lacking inverse agonist properties. J Pharmacol Exp Ther 323:374-80
Jinsmaa, Yunden; Marczak, Ewa; Fujita, Yoshio et al. (2006) Potent in vivo antinociception and opioid receptor preference of the novel analogue [Dmt1]endomorphin-1. Pharmacol Biochem Behav 84:252-8
Vazquez, M Eugenio; Blanco, Juan B; Salvadori, Severo et al. (2006) 6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides. J Med Chem 49:3653-8
Li, Tingyou; Tsuda, Yuko; Minoura, Katsuhiko et al. (2006) Enantioselective synthesis of a phenylalanine library containing alkyl groups on the aromatic moiety: confirmation of stereostructure by x-ray analysis. Chem Pharm Bull (Tokyo) 54:873-7
Jinsmaa, Yunden; Fujita, Yoshio; Shiotani, Kimitaka et al. (2005) Differentiation of opioid receptor preference by [Dmt1]endomorphin-2-mediated antinociception in the mouse. Eur J Pharmacol 509:37-42
In, Yasuko; Minoura, Katsuhiko; Tomoo, Koji et al. (2005) Structural function of C-terminal amidation of endomorphin. Conformational comparison of mu-selective endomorphin-2 with its C-terminal free acid, studied by 1H-NMR spectroscopy, molecular calculation, and X-ray crystallography. FEBS J 272:5079-97
Fujita, Yoshio; Tsuda, Yuko; Motoyama, Takashi et al. (2005) Studies on the structure-activity relationship of 2',6'-dimethyl-l-tyrosine (Dmt) derivatives: bioactivity profile of H-Dmt-NH-CH(3). Bioorg Med Chem Lett 15:599-602

Showing the most recent 10 out of 31 publications